

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**三生制药**  
**3SBIO INC.**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1530)**

## **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CONNECTED TRANSACTION ON GRANT OF SHARE AWARDS TO CONNECTED PERSONS PURSUANT TO THE SHARE AWARD SCHEME**

Reference is made to the announcement of the Company dated 23 September 2024 (the “**Announcement**”) in relation to, among others, the grant of Awards to the Grantees pursuant to the Share Award Scheme. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

In addition to the information contained in the Announcement, the Board hereby provides supplemental information on the grant of Awards to the Grantees pursuant to the Share Award Scheme. Dr. LOU Jing is one of the Grantees and accordingly he is considered to have a material interest in the grant of Awards and therefore had abstained from voting at the Board meeting approving the grant of Awards to the Grantees pursuant to the Share Award Scheme.

Save as disclosed above, all other information and contents set out in the Announcement remain unchanged.

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Hong Kong SAR, the PRC  
24 September 2024

*As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Ms. ZHANG Jiaoe as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.*